|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
PL401638A1
(pl)
*
|
2002-03-13 |
2013-05-27 |
Array Biopharma Inc. |
N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
|
|
US20060084682A1
(en)
*
|
2002-12-13 |
2006-04-20 |
Heerding Dirk A |
Thrombopoietin mimetics
|
|
ES2324165T3
(es)
*
|
2003-02-26 |
2009-07-31 |
Kowa Co., Ltd. |
Tratamiento de la dermatitis alergica de contacto.
|
|
WO2005009975A2
(en)
|
2003-07-24 |
2005-02-03 |
Warner-Lambert Company Llc |
Benzimidazole derivatives as mek inhibitors
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
*
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
TWI349664B
(en)
|
2003-09-22 |
2011-10-01 |
S Bio Pte Ltd |
Benzimidazole derivatives: preparation and pharmaceutical applications
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
JP4768628B2
(ja)
*
|
2003-11-19 |
2011-09-07 |
アレイ バイオファーマ、インコーポレイテッド |
Ｍｅｋの二環系阻害剤及びその使用方法
|
|
US7517994B2
(en)
*
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
AU2004293026B2
(en)
*
|
2003-11-21 |
2012-01-19 |
Array Biopharma Inc. |
AKT protein kinase inhibitors
|
|
EP1699477A2
(en)
*
|
2003-12-11 |
2006-09-13 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
PT1802579E
(pt)
|
2004-10-20 |
2014-02-17 |
Merck Serono Sa |
Derivados da 3-arilaminopiridina
|
|
AU2005311451A1
(en)
*
|
2004-12-01 |
2006-06-08 |
Merck Serono Sa |
[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
|
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
EP1967516B1
(en)
|
2005-05-18 |
2009-11-04 |
Array Biopharma, Inc. |
4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases
|
|
EP1904061B1
(en)
*
|
2005-06-23 |
2018-12-26 |
Array Biopharma, Inc. |
SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
|
|
US8039637B2
(en)
|
2005-06-23 |
2011-10-18 |
Array Biopharma Inc. |
Process for preparing benzimidazole compounds
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
AU2013203939B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
AU2012261703B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
US7968108B2
(en)
*
|
2005-10-25 |
2011-06-28 |
Metbro Distributing L.P. |
Hydrogen cyanamide pesticide formulations
|
|
US7572460B2
(en)
*
|
2005-10-25 |
2009-08-11 |
Rodrigo Rodriguez-Kabana |
Hydrogen cyanamide pesticide formulations
|
|
TWI405756B
(zh)
*
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
|
RU2418790C3
(ru)
*
|
2005-12-21 |
2022-03-14 |
Астразенека Аб |
Новая гидросульфатная соль
|
|
US20090030058A1
(en)
*
|
2005-12-21 |
2009-01-29 |
Mohammed Pervez |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
CA2534243A1
(fr)
|
2006-01-25 |
2007-07-25 |
Hydro Quebec |
Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
|
WO2007121481A2
(en)
*
|
2006-04-18 |
2007-10-25 |
Ardea Biosciences, Inc. |
Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
|
|
SI2054418T1
(sl)
|
2006-07-06 |
2012-02-29 |
Array Biopharma Inc |
Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
|
|
DK2049500T3
(da)
|
2006-07-06 |
2011-12-12 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
|
|
WO2008006025A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
WO2008016123A1
(en)
*
|
2006-08-03 |
2008-02-07 |
Takeda Pharmaceutical Company Limited |
GSK-3β INHIBITOR
|
|
CA2660546A1
(en)
*
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
|
CN101583616B
(zh)
*
|
2006-08-21 |
2012-05-30 |
健泰科生物技术公司 |
氮杂苯并噻吩基化合物及使用方法
|
|
JP5349306B2
(ja)
|
2006-08-21 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
アザベンゾチオフェニル化合物および使用方法
|
|
JP5311673B2
(ja)
|
2006-12-14 |
2013-10-09 |
エグゼリクシス， インコーポレイテッド |
Ｍｅｋ阻害剤の使用方法
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
WO2008125820A1
(en)
*
|
2007-04-13 |
2008-10-23 |
Astrazeneca Ab |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
|
US8509487B2
(en)
*
|
2007-04-19 |
2013-08-13 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
System and method for optically measuring a parameter of an object
|
|
WO2008157179A2
(en)
|
2007-06-12 |
2008-12-24 |
Genentech, Inc. |
N-substituted azaindoles and methods of use
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
KR20150091196A
(ko)
|
2007-07-05 |
2015-08-07 |
어레이 바이오파마 인크. |
Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
|
|
CN101801955B
(zh)
|
2007-07-05 |
2013-05-08 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
MX2010004074A
(es)
*
|
2007-10-15 |
2010-07-02 |
Astrazeneca Ab |
Combinacion 059.
|
|
US8022057B2
(en)
|
2007-11-12 |
2011-09-20 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
CA2704125A1
(en)
|
2007-12-19 |
2009-07-09 |
Genentech, Inc. |
8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
|
|
NZ586802A
(en)
|
2007-12-19 |
2012-03-30 |
Genentech Inc |
Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases
|
|
CN101896469A
(zh)
|
2007-12-20 |
2010-11-24 |
霍夫曼-拉罗奇有限公司 |
作为mek激酶抑制剂的取代的乙内酰脲类化合物
|
|
US8486963B2
(en)
|
2007-12-21 |
2013-07-16 |
Genentech, Inc. |
Azaindolizines and methods of use
|
|
KR101624752B1
(ko)
|
2008-01-09 |
2016-05-26 |
어레이 바이오파마 인크. |
Ａｋｔ 단백질 키나제 저해물질로써의 수산화된 피리미딜 시클로펜탄
|
|
CA2711699A1
(en)
*
|
2008-01-09 |
2009-07-16 |
Array Biopharma Inc. |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
SA109300195B1
(ar)
|
2008-03-28 |
2013-04-20 |
Astrazeneca Ab |
تركيبة صيدلانية جديدة مضادة للسرطان
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
JP5404622B2
(ja)
|
2008-06-23 |
2014-02-05 |
パナソニック株式会社 |
無線通信基地局装置および参照信号割当方法
|
|
CN102137843A
(zh)
*
|
2008-07-01 |
2011-07-27 |
健泰科生物技术公司 |
作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
|
|
CA2727250A1
(en)
|
2008-07-01 |
2010-01-07 |
Genentech, Inc. |
Bicyclic heterocycles as mek kinase inhibitors
|
|
HUE027223T2
(en)
|
2008-08-04 |
2016-08-29 |
Merck Patent Gmbh |
New Phenylamino Isonicotinamide Compounds
|
|
CN101653607B
(zh)
*
|
2008-08-19 |
2013-02-13 |
鼎泓国际投资（香港）有限公司 |
含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
|
|
US8470819B2
(en)
*
|
2008-11-03 |
2013-06-25 |
Merck Sharp & Dohme Corp. |
Benzimidazole and aza-benzimidazole carboxamides
|
|
EP2346818B1
(en)
|
2008-11-10 |
2012-12-05 |
Bayer Intellectual Property GmbH |
Substituted sulphonamido phenoxybenzamides
|
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
CA2777430A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
EP2491014A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
WO2011047788A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
|
KR20130048293A
(ko)
|
2010-06-25 |
2013-05-09 |
노파르티스 아게 |
단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
|
|
US20150141380A1
(en)
|
2010-08-05 |
2015-05-21 |
Case Western Reserve University |
Inhibitors of erk for developmental disorders of neuronal connectivity
|
|
PT2624696T
(pt)
|
2010-10-06 |
2017-03-21 |
Glaxosmithkline Llc |
Derivados de benzimidazole como inibidores da cinase pi3
|
|
WO2012055953A1
(en)
|
2010-10-29 |
2012-05-03 |
Bayer Pharma Aktiengesellschaft |
Substituted phenoxypyridines
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
KR20200113286A
(ko)
|
2010-12-22 |
2020-10-06 |
페이트 세러퓨틱스, 인코포레이티드 |
단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
|
|
EP2655375B1
(fr)
|
2010-12-23 |
2014-12-03 |
Sanofi |
Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
|
|
WO2012135759A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and abiraterone, and methods of use
|
|
CN103841976A
(zh)
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt和mek抑制剂化合物的组合及其使用方法
|
|
WO2012145503A1
(en)
|
2011-04-21 |
2012-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
US20140228418A1
(en)
*
|
2011-05-23 |
2014-08-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
ES2834093T3
(es)
|
2011-07-21 |
2021-06-16 |
Sumitomo Dainippon Pharma Oncology Inc |
Inhibidores de proteína quinasa heterocíclicos
|
|
AR087405A1
(es)
*
|
2011-08-01 |
2014-03-19 |
Genentech Inc |
Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
|
|
US10813630B2
(en)
|
2011-08-09 |
2020-10-27 |
Corquest Medical, Inc. |
Closure system for atrial wall
|
|
US10307167B2
(en)
|
2012-12-14 |
2019-06-04 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
US10314594B2
(en)
|
2012-12-14 |
2019-06-11 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
US9675595B2
(en)
|
2011-08-31 |
2017-06-13 |
Novartis Ag |
Synergistic combinations of PI3K- and MEK-inhibitors
|
|
MX2014002480A
(es)
*
|
2011-09-01 |
2014-03-27 |
Novartis Ag |
Uso del compuesto organico para el tratamiento del sindrome de noonan.
|
|
EP2570127A1
(en)
|
2011-09-16 |
2013-03-20 |
Sanofi |
Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
|
|
KR20200003245A
(ko)
|
2011-10-14 |
2020-01-08 |
어레이 바이오파마 인크. |
선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
|
|
WO2013067162A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とｈｓｐ９０阻害剤の組合せ療法
|
|
CA2854188A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
|
MX350957B
(es)
|
2011-11-23 |
2017-09-27 |
Medimmune Llc |
Moleculas de union especificas para her3 y usos de las mismas.
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
EP2802658A2
(en)
|
2012-01-09 |
2014-11-19 |
Novartis AG |
Rnai agents to treat beta-catenin related diseases
|
|
WO2013109142A1
(en)
|
2012-01-16 |
2013-07-25 |
Stichting Het Nederlands Kanker Instituut |
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
BR112014023423A2
(pt)
*
|
2012-03-20 |
2017-07-11 |
Amgen Inc |
terapia de combinação
|
|
WO2013152425A1
(en)
|
2012-04-09 |
2013-10-17 |
Switch Materials , Inc. |
Switching materials, and compositions and methods for making same
|
|
CN104508520B
(zh)
|
2012-05-29 |
2018-03-27 |
思维奇材料公司 |
包含可变透射率层的滤光片
|
|
US20150267258A1
(en)
|
2012-05-31 |
2015-09-24 |
Bayer Pharma Aktiengesellschaft |
Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
RS59113B1
(sr)
|
2012-08-17 |
2019-09-30 |
Hoffmann La Roche |
Kombinovane terapije za melanom koje uključuju davanje kobimetiniba i vemurafiniba
|
|
US20150203453A1
(en)
|
2012-10-02 |
2015-07-23 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
|
UA115455C2
(uk)
|
2012-10-12 |
2017-11-10 |
Екселіксіс, Інк. |
Спосіб одержання сполук для застосування при лікуванні раку
|
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
|
SI2909182T1
(sl)
|
2012-10-19 |
2020-03-31 |
Array Biopharma Inc. |
Priprava inhibitorja MEK in formulacije, ki obsegajo inhibitor MEK
|
|
US20140142689A1
(en)
|
2012-11-21 |
2014-05-22 |
Didier De Canniere |
Device and method of treating heart valve malfunction
|
|
EP2925366B1
(en)
|
2012-11-29 |
2018-02-21 |
Novartis AG |
Pharmaceutical combinations
|
|
US9867825B2
(en)
|
2012-12-20 |
2018-01-16 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
AU2014218807A1
(en)
|
2013-02-22 |
2015-09-03 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
JP6514117B2
(ja)
|
2013-02-27 |
2019-05-15 |
エピセラピューティクス アーペーエス |
ヒストン脱メチル化酵素の阻害剤
|
|
US10139415B2
(en)
|
2013-02-27 |
2018-11-27 |
Daiichi Sankyo Company, Limited |
Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
|
|
AU2014236820B2
(en)
|
2013-03-14 |
2018-08-02 |
Sumitomo Pharma Oncology, Inc. |
JAK2 and ALK2 inhibitors and methods for their use
|
|
CA2907704C
(en)
*
|
2013-03-21 |
2023-01-10 |
Giordano Caponigro |
Combination therapy for reversing b-raf inhibitor resistance comprising a second inhibitor based on genetic alterations
|
|
AR097617A1
(es)
|
2013-09-13 |
2016-04-06 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos del 2h-indazol
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US9629851B2
(en)
|
2013-09-20 |
2017-04-25 |
Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis |
ROCK in combination with MAPK pathway
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
US9566443B2
(en)
|
2013-11-26 |
2017-02-14 |
Corquest Medical, Inc. |
System for treating heart valve malfunction including mitral regurgitation
|
|
ES2666130T3
(es)
|
2013-12-19 |
2018-05-03 |
Idorsia Pharmaceuticals Ltd |
Derivados antibacterianos de 1H-indazol y 1H-indol
|
|
CA2935804A1
(en)
|
2014-01-14 |
2015-07-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
AR099612A1
(es)
|
2014-03-04 |
2016-08-03 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
|
|
EP4647498A2
(en)
|
2014-03-04 |
2025-11-12 |
Fate Therapeutics, Inc. |
Improved reprogramming methods and cell culture platforms
|
|
KR20240110004A
(ko)
|
2014-03-14 |
2024-07-12 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
AR099890A1
(es)
|
2014-03-31 |
2016-08-24 |
Epitherapeutics Aps |
Inhibidores de histona demetilasas
|
|
US20170107486A1
(en)
|
2014-04-21 |
2017-04-20 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
KR20170005105A
(ko)
|
2014-05-16 |
2017-01-11 |
액테리온 파마슈티칼 리미티드 |
항균성 퀴나졸린-４(３ｈ)-온 유도체
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
SG10202007111TA
(en)
|
2014-07-15 |
2020-09-29 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
CA2957947A1
(en)
|
2014-08-27 |
2016-03-03 |
Gilead Sciences, Inc. |
Compounds and methods for inhibiting histone demethylases
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
|
CA2963091A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
US10842626B2
(en)
|
2014-12-09 |
2020-11-24 |
Didier De Canniere |
Intracardiac device to correct mitral regurgitation
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
UA120945C2
(uk)
|
2014-12-23 |
2020-03-10 |
Новартіс Аг |
Сполуки триазолопіримідину та їх застосування
|
|
SG11201706041XA
(en)
|
2015-01-26 |
2017-08-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CN105566225A
(zh)
*
|
2015-02-16 |
2016-05-11 |
苏州晶云药物科技有限公司 |
一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
|
JP6695353B2
(ja)
|
2015-03-25 |
2020-05-20 |
ノバルティス アーゲー |
Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
AR105646A1
(es)
|
2015-08-11 |
2017-10-25 |
Actelion Pharmaceuticals Ltd |
Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
|
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
|
CN111821306A
(zh)
|
2015-08-28 |
2020-10-27 |
诺华股份有限公司 |
Mdm2抑制剂和其组合
|
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
HRP20220436T1
(hr)
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Protutijela koja se specifično vežu na pd-1 i njihove uporabe
|
|
SG11201803144WA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Genomic engineering of pluripotent cells
|
|
EP3371301A4
(en)
|
2015-11-04 |
2019-06-26 |
Fate Therapeutics, Inc. |
METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
|
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
JP7616817B2
(ja)
|
2016-01-20 |
2025-01-17 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
AU2017226389B2
(en)
|
2016-03-04 |
2023-02-02 |
Taiho Pharmaceutical Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
UA125436C2
(uk)
|
2016-06-03 |
2022-03-09 |
Еррей Біофарма, Інк. |
Фармацевтичні комбінації
|
|
EP3472166A1
(en)
|
2016-06-20 |
2019-04-24 |
Novartis AG |
Imidazopyrimidine compounds useful for the treatment of cancer
|
|
JP7042812B2
(ja)
|
2016-06-20 |
2022-03-28 |
ノバルティス アーゲー |
トリアゾロピリミジン化合物の結晶形態
|
|
US10689378B2
(en)
|
2016-06-20 |
2020-06-23 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
WO2018065924A1
(en)
*
|
2016-10-04 |
2018-04-12 |
Sun Pharmaceutical Industries Limited |
Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
CN108084078B
(zh)
*
|
2016-11-24 |
2021-07-30 |
中山大学 |
一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
|
|
JP7098615B2
(ja)
|
2016-12-05 |
2022-07-11 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
EP3372624A1
(en)
|
2017-03-06 |
2018-09-12 |
Henkel AG & Co. KGaA |
One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
CN111646946A
(zh)
*
|
2017-11-14 |
2020-09-11 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的苯并咪唑化合物及包含该化合物的组合物
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
PL3769765T3
(pl)
|
2018-03-19 |
2024-06-10 |
Taiho Pharmaceutical Co., Ltd. |
Kompozycja farmaceutyczna zawierająca alkilosiarczan sodu
|
|
EP3773591A4
(en)
|
2018-04-05 |
2021-12-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
AXL KINASE INHIBITORS AND THEIR USE
|
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
DE202018007007U1
(de)
|
2018-07-25 |
2025-10-08 |
Advanced Accelerator Applications S.A. |
Stabile, konzentrierte Radionuklidkomplexlösungen
|
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
|
US11958846B2
(en)
|
2018-08-17 |
2024-04-16 |
Novartis Ag |
Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
|
|
CN112867512A
(zh)
|
2018-09-25 |
2021-05-28 |
意大利国际先进加速器应用有限公司 |
联合疗法
|
|
MA55141A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés cyanoaryl-aniline pour le traitement d'affections de la peau
|
|
JP7393808B2
(ja)
|
2018-11-20 |
2023-12-07 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのナフチリジノン－アニリン化合物
|
|
CN117551073A
(zh)
|
2018-11-20 |
2024-02-13 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病噻吩基苯胺化合物
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
|
|
HUE072069T2
(hu)
|
2019-02-12 |
2025-10-28 |
Sumitomo Pharma America Inc |
2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
CN113329792B
(zh)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
AU2020242287A1
(en)
|
2019-03-21 |
2021-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
EP3941463A1
(en)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020212832A1
(en)
*
|
2019-04-16 |
2020-10-22 |
Alembic Pharmaceuticals Limited |
Process of preparation of benzimidazole compounds
|
|
BR112021020532A2
(pt)
|
2019-04-19 |
2022-03-15 |
Janssen Biotech Inc |
Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
|
|
TWI817018B
(zh)
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
WO2021057853A1
(en)
|
2019-09-26 |
2021-04-01 |
Novartis Ag |
Aza-quinoline compounds and uses thereof
|
|
KR20220098759A
(ko)
|
2019-11-08 |
2022-07-12 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
키나제 억제제에 대해 내성을 획득한 암의 치료 방법
|
|
WO2021116901A1
(en)
*
|
2019-12-09 |
2021-06-17 |
Biocon Limited |
Forms of binimetinib and process for preparation thereof
|
|
AU2020406350A1
(en)
|
2019-12-20 |
2022-08-11 |
Novartis Ag |
Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN115380026B
(zh)
*
|
2020-03-17 |
2023-11-07 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
TW202200146A
(zh)
|
2020-04-10 |
2022-01-01 |
日商大鵬藥品工業股份有限公司 |
使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法
|
|
WO2021250521A1
(en)
|
2020-06-09 |
2021-12-16 |
Array Biopharma Inc. |
4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
AU2021358394A1
(en)
|
2020-10-05 |
2023-04-13 |
Pierre Fabre Medicament |
Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
CN112759552A
(zh)
*
|
2020-12-31 |
2021-05-07 |
武汉九州钰民医药科技有限公司 |
司美替尼的合成方法
|
|
CN112679438A
(zh)
*
|
2020-12-31 |
2021-04-20 |
武汉九州钰民医药科技有限公司 |
制备司美替尼的方法
|
|
US12141240B2
(en)
|
2021-01-20 |
2024-11-12 |
Rutgers, The State University Of New Jersey |
Method of calibration using master calibration function
|
|
WO2022159600A1
(en)
*
|
2021-01-21 |
2022-07-28 |
Nflection Therapeutics, Inc. |
Processes for preparing pyrrolopyridine-aniline compounds
|
|
CA3210246A1
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
IL304891A
(en)
|
2021-02-02 |
2023-10-01 |
Servier Lab |
Selective Protech BCL-XL compounds and methods of use
|
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022221227A1
(en)
|
2021-04-13 |
2022-10-20 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
EP4322953A4
(en)
*
|
2021-04-15 |
2025-01-22 |
Ideaya Biosciences, Inc. |
COMBINATION THERAPY WITH A PKC INHIBITOR AND A MEK INHIBITOR
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
JP2024521788A
(ja)
|
2021-05-27 |
2024-06-04 |
ミラティ セラピューティクス， インコーポレイテッド |
併用療法
|
|
TW202313046A
(zh)
|
2021-06-09 |
2023-04-01 |
瑞士商赫孚孟拉羅股份公司 |
用於癌症治療之組合療法
|
|
CN115490640B
(zh)
*
|
2021-06-17 |
2024-11-26 |
深圳市塔吉瑞生物医药有限公司 |
取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
|
|
CA3226162A1
(en)
|
2021-07-09 |
2023-01-12 |
Plexium, Inc. |
Aryl compounds and pharmaceutical compositions that modulate ikzf2
|
|
AU2022383040A1
(en)
|
2021-11-04 |
2024-03-07 |
F. Hoffmann-La Roche Ag |
Novel use of quinazolinone compound for the treatment of cancer
|
|
WO2023084489A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
IL317103A
(en)
|
2022-05-20 |
2025-01-01 |
Novartis Ag |
Antibody-drug conjugates of MET inhibitor BCL-XL and methods of using them
|
|
EP4525925A1
(en)
|
2022-05-20 |
2025-03-26 |
Novartis AG |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
EP4536226A1
(en)
*
|
2022-06-06 |
2025-04-16 |
Alivus Life Sciences Limited |
Process for preparation of selumetinib and salts thereof
|
|
EP4618994A1
(en)
|
2022-11-18 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
|
|
AU2024234194A1
(en)
|
2023-03-10 |
2025-08-07 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
CN120813358A
(zh)
|
2023-04-06 |
2025-10-17 |
卫材R&D管理有限公司 |
用于治疗肿瘤的药物组合物
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
FR3159741A1
(fr)
|
2024-03-04 |
2025-09-05 |
Pierre Fabre Medicament |
Formulation topique comprenant du binimetinib
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
PL451046A1
(pl)
*
|
2025-01-27 |
2025-06-09 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451045A1
(pl)
*
|
2025-01-27 |
2025-06-09 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451050A1
(pl)
*
|
2025-01-27 |
2025-08-04 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451049A1
(pl)
*
|
2025-01-27 |
2025-08-04 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451047A1
(pl)
*
|
2025-01-27 |
2025-08-18 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|
|
PL451048A1
(pl)
*
|
2025-01-27 |
2025-08-04 |
Politechnika Lubelska |
Kompozytowa konstrukcja przekładkowa
|